Alto Neuroscience, Inc. – NYSE:ANRO
Alto Neuroscience stock price today
Alto Neuroscience stock price monthly change
Alto Neuroscience stock price quarterly change
Alto Neuroscience key metrics
Market Cap | 105.18M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAlto Neuroscience stock price history
Alto Neuroscience stock forecast
Alto Neuroscience financial statements
$10
Potential upside: 185.71%
Analysts Price target
Financials & Ratios estimates
| 2023 | 0 | -36.30M |
|---|
| 2024-03-21 | -1.67 | -7.77 |
|---|---|---|
| 2024-05-14 | -0.46 | -0.76 |
| 2023 | 86628000 | 158.3M | 182.74% |
|---|
| 2022 | -20.39M | -732K | 43.78M |
|---|---|---|---|
| 2023 | -33.44M | -470K | 68.13M |
Alto Neuroscience alternative data
| Jun 2024 | 67 |
|---|---|
| Jul 2024 | 67 |
| Dec 2024 | 78 |
Alto Neuroscience other data
| Period | Buy | Sel |
|---|---|---|
| Jul 2024 | 15000 | 0 |
-
What's the price of Alto Neuroscience stock today?
One share of Alto Neuroscience stock can currently be purchased for approximately $3.5.
-
When is Alto Neuroscience's next earnings date?
Unfortunately, Alto Neuroscience's (ANRO) next earnings date is currently unknown.
-
Does Alto Neuroscience pay dividends?
No, Alto Neuroscience does not pay dividends.
-
How much money does Alto Neuroscience make?
Alto Neuroscience has a market capitalization of 105.18M. Alto Neuroscience made a loss 36.31M US dollars in net income (profit) last year or -$0.76 on an earnings per share basis.
-
What is Alto Neuroscience's stock symbol?
Alto Neuroscience, Inc. is traded on the NYSE under the ticker symbol "ANRO".
-
What is Alto Neuroscience's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Alto Neuroscience?
Shares of Alto Neuroscience can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Alto Neuroscience have?
As Dec 2024, Alto Neuroscience employs 78 workers, which is 16% more then previous month.
-
When Alto Neuroscience went public?
Alto Neuroscience, Inc. is publicly traded company for just a year since IPO on 2 Feb 2024.
-
What is Alto Neuroscience's official website?
The official website for Alto Neuroscience is altoneuroscience.com.
-
Where are Alto Neuroscience's headquarters?
Alto Neuroscience is headquartered at 369 South San Antonio Road, Los Altos, CA.
-
How can i contact Alto Neuroscience?
Alto Neuroscience's mailing address is 369 South San Antonio Road, Los Altos, CA and company can be reached via phone at +65 02000412.
-
What is Alto Neuroscience stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Alto Neuroscience in the last 12 months, the avarage price target is $10. The average price target represents a 185.71% change from the last price of $3.5.
Alto Neuroscience company profile:
Alto Neuroscience, Inc.
altoneuroscience.comNYSE
78
Biotechnology
Healthcare
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.
Los Altos, CA 94022
CIK: 0001999480
ISIN: US02157Q1094
:
